Fresenius SE & Co. (OTCMKTS:FSNUY) Stock Short Interest Report for October

Fresenius SE & Co. (OTCMKTS:FSNUY) was the recipient of a significant growth in short interest in October. As of October 15th, there was short interest totaling 367,297 shares, a growth of 1,170.7% from the September 30th total of 28,906 shares. Based on an average trading volume of 1,015,424 shares, the short-interest ratio is currently 0.4 days. Currently, 0.0% of the company’s shares are sold short.

Fresenius SE & Co. Stock Up 0.9%

FSNUY traded up $0.11 on Monday, hitting $12.99. The company had a trading volume of 97,381 shares, compared to its average volume of 170,762. The stock has a market capitalization of $29.27 billion, a price-to-earnings ratio of 16.44 and a beta of 0.60. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.97 and a current ratio of 1.28. The stock has a fifty day moving average price of $12.95 and a 200-day moving average price of $12.91. Fresenius SE & Co. has a 12-month low of $10.33 and a 12-month high of $33.93.

Fresenius SE & Co. (OTCMKTS:FSNUY) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.24 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Fresenius SE & Co. had a net margin of 6.67% and a return on equity of 10.25%. The firm had revenue of $6.91 billion during the quarter, compared to the consensus estimate of $6.65 billion. Analysts predict that Fresenius SE & Co. will post 1.08 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a research note on Tuesday, July 21st. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Fresenius SE & Co. in a research report on Thursday, August 6th. Three equities research analysts have rated the stock with a Buy rating. According to data from MarketBeat, the company currently has an average rating of “Buy”.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a Germany-based global health care group that develops and provides products, services and technologies for hospitals, clinics and patients. The company’s activities are focused primarily on health care products and therapies, as well as the operation of hospitals and other medical facilities.

Fresenius Kabi, one of the company’s core businesses, supplies medicines and therapies for critically and chronically ill patients, including intravenous drugs, clinical nutrition, infusion therapies, medical devices and related services.